Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2024

Open Access 01-12-2024 | Chlamydophila Pneumoniae | Research

Longitudinal analysis of quality of life in primary lung cancer patients with chlamydia pneumoniae infection: a time-to-deterioration model

Authors: Zishan Chen, Jinman Zhuang, Maolin Liu, Xinying Xu, Yuhang Liu, Shuyan Yang, Jinbao Xie, Nanlong Lin, Fancai Lai, Fei He

Published in: BMC Pulmonary Medicine | Issue 1/2024

Login to get access

Abstract

Background

Chlamydia pneumoniae (Cpn) IgG and IgA has been strongly linked to lung cancer, but its impact on patients' quality of life remains unclear. Our objective was to investigate the relationship between pre-treatment Cpn IgG and IgA and time to deterioration (TTD) of the HRQoL in patients with primary lung cancer.

Methods

A prospective hospital-based study was conducted from June 2017 to December 2018, enrolling 82 patients with primary lung cancer admitted to the First Affiliated Hospital of Fujian Medical University for questionnaire surveys. Cpn IgG and IgA was detected by microimmunofluorescence method. HRQoL was assessed at baseline and during follow-up using the EORTC Quality of Life Questionnaire version 3.0 (EORTC QLQ-C30) and EORTC Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13). HRQoL scores were calculated using the QoLR package, and TTD events were determined (minimum clinically significant difference = 5 points). Cox regression analysis was used to evaluate the effect of Cpn IgG and IgA on HRQoL.

Results

We investigated the relationship between Cpn IgG and IgA and quality of life in patients with primary lung cancer. The study was found that 75.61% of cases were Cpn IgG + and 45.12% were Cpn IgA + . Cpn IgA + IgG + was 41.46%. For EORTC QLQ-C30, Physical function (PF) and Pain (PA) TTD events on the functional scale and Symptom scale were the most common during follow-up. After adjusting for gender and smoking status, Pre-treatment Cpn IgA + was found to signifcantly delay TTD of Physical functioning(HR = 0.539, 95% CI: 0.291–0.996, P = 0.048). In addition, Cpn IgG + before treatment significantly delayed TTD in Emotional functioning (HR = 0.310, 95% CI: 0.115–0.836, P = 0.021). For EORTC QLQ-LC13, deterioration of dyspnea (LC-DY) was the most common event. However, Cpn IgG and IgA before treatment had no effect on the TTD of EORTC QLQ-LC13 items.

Conclusions

According to EORTC QLQ-C30 and EORTC QLQ-LC13, Cpn IgA delayed TTD in Physical functioning and Cpn IgG delayed TTD in Emotional functioning.
Literature
1.
Bai X, Liu X, Li S, An H, Kang X, Guo S. Nuciferine Inhibits TMEM16A in Dietary Adjuvant Therapy for Lung Cancer. J Agric Food Chem. 2022;70(12):3687–96.CrossRefPubMed
2.
Wang Y, Liu F, OuYang S, Liu M, Zhang X, Wang P, et al. Humoral immune response to epidermal growth factor receptor in lung cancer. Immunol Res. 2021;69(1):71–80.CrossRefPubMed
3.
Colt HG, Murgu SD, Korst RJ, Slatore CG, Unger M, Quadrelli S. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e437S – e454.CrossRefPubMed
4.
5.
Hassen AM, Taye G, Gizaw M, Hussien FM. Quality of life and associated factors among patients with breast cancer under chemotherapy at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. PLoS ONE. 2019;14(9): e0222629.CrossRefPubMedPubMedCentral
6.
Sosnowski R, Kulpa M, Ziętalewicz U, Wolski JK, Nowakowski R, Bakuła R, Demkow T. Basic issues concerning health-related quality of life. Cent European J Urol. 2017;70(2):206–11.PubMedPubMedCentral
7.
Han X, Robinson LA, Jensen RE, Smith TG, Yabroff KR. Factors Associated With Health-Related Quality of Life Among Cancer Survivors in the United States. JNCI Cancer Spectr. 2021;5(1):pkaa123.
8.
Kim K, Yoon H. Health-Related Quality of Life among Cancer Survivors Depending on the Occupational Status. Int J Environ Res Public Health. 2021;18(7):3803.
9.
Wu M, Mou R, Liu X, Guo S, Kong F, Li X, Jia Y. Is COVID-19 a high risk factor for lung cancer?: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021;100(1): e23877.CrossRefPubMed
10.
Consoli D, Vidale S, Arnaboldi M, Cavallini A, Consoli A, Galati F, et al. Infections and Chlamydia pneumoniae antibodies influence the functional outcome in thrombolysed strokes. J Neurol Sci. 2017;381:95–9.CrossRefPubMed
11.
Matsuo J, Sakai K, Okubo T, Yamaguchi H. Chlamydia pneumoniae enhances Interleukin 8 (IL-8) production with reduced azithromycin sensitivity under hypoxia. APMIS. 2019;127(3):131–8.CrossRefPubMed
12.
Xu X, Liu Z, Xiong W, Qiu M, Kang S, Xu Q, et al. Combined and interaction effect of chlamydia pneumoniae infection and smoking on lung cancer: a case-control study in Southeast China. BMC Cancer. 2020;20(1):903.CrossRefPubMedPubMedCentral
13.
Bonnetain F, Dahan L, Maillard E, Ychou M, Mitry E, Hammel P, et al. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer. 2010;46(15):2753–62.CrossRefPubMed
14.
Brusniak K, Feisst M, Sebesteny L, Hartkopf A, Graf J, Engler T, et al. Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study. JMIR Cancer. 2021;7(4): e25776.CrossRefPubMedPubMedCentral
15.
Hamidou Z, Dabakuyo TS, Mercier M, Fraisse J, Causeret S, Tixier H, et al. Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancer. Oncologist. 2011;16(10):1458–68.CrossRefPubMedPubMedCentral
16.
Nolte S, Liegl G, Petersen MA, Aaronson NK, Costantini A, Fayers PM, et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur J Cancer. 2019;107:153–63.CrossRefPubMed
17.
Koller M, Hjermstad MJ, Tomaszewski KA, Tomaszewska IM, Hornslien K, Harle A, et al. An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients. Ann Oncol. 2017;28(11):2874–81.CrossRefPubMed
18.
Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–44.CrossRefPubMed
19.
Jaeschke R, Singer J, Guyatt GH. Measurement of health status Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407–15.CrossRefPubMed
20.
Hua-Feng X, Yue-Ming W, Hong L, Junyi D. A meta-analysis of the association between Chlamydia pneumoniae infection and lung cancer risk. Indian J Cancer. 2015;52(Suppl 2):e112–5.PubMed
21.
Zhan P, Suo LJ, Qian Q, Shen XK, Qiu LX, Yu LK, Song Y. Chlamydia pneumoniae infection and lung cancer risk: a meta-analysis. Eur J Cancer. 2011;47(5):742–7.CrossRefPubMed
22.
Qunxia C, Lin C. Meta analysis of the relationship between Chlamydia pneumoniae infection and lung cancer serological research. Chin J Publ Heal. 2015;31(08):1095–9.
23.
Koyi H, Brandén E, Gnarpe J, Gnarpe H, Steen B. An association between chronic infection with Chlamydia pneumoniae and lung cancer. A prospective 2-year study Apmis. 2001;109(9):572–80.PubMed
24.
Paldanius M, Bloigu A, Leinonen M, Saikku P. Measurement of Chlamydia pneumoniae-specific immunoglobulin A (IgA) antibodies by the microimmunofluorescence (MIF) method: comparison of seven fluorescein-labeled anti-human IgA conjugates in an in-house MIF test using one commercial MIF and one enzyme immunoassay kit. Clin Diagn Lab Immunol. 2003;10(1):8–12.PubMedPubMedCentral
25.
Metadata
Title
Longitudinal analysis of quality of life in primary lung cancer patients with chlamydia pneumoniae infection: a time-to-deterioration model
Authors
Zishan Chen
Jinman Zhuang
Maolin Liu
Xinying Xu
Yuhang Liu
Shuyan Yang
Jinbao Xie
Nanlong Lin
Fancai Lai
Fei He
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-024-02860-x

Other articles of this Issue 1/2024

BMC Pulmonary Medicine 1/2024 Go to the issue

Research

Genetically determined gut microbiota associates with pulmonary arterial hypertension: a Mendelian randomization study

Research

Attributable mortality of ARDS among critically ill patients with sepsis: a multicenter, retrospective cohort study

Research

Effects of triple therapy on disease burden in patients of GOLD groups C and D: results from the observational COPD cohort COSYCONET

Study Protocol

The Fractional exhaled Nitric Oxide (FeNO)- test as add-on test in the diagnostic work-up of asthma: a study protocol

Research

A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials

Research

High-sensitivity C-reactive protein level in stable-state bronchiectasis predicts exacerbation risk
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits